Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ZYME 
Zymeworks Inc. Common Stock (ZYME)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: ZYME (3-star) is a STRONG-BUY. BUY since 15 days. Simulated Profits (4.24%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $21.05
1 Year Target Price $21.05
| 7 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 69.97% | Avg. Invested days 39 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.19B USD | Price to earnings Ratio - | 1Y Target Price 21.05 |
Price to earnings Ratio - | 1Y Target Price 21.05 | ||
Volume (30-day avg) 10 | Beta 1.27 | 52 Weeks Range 9.03 - 17.70 | Updated Date 09/14/2025 |
52 Weeks Range 9.03 - 17.70 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.98 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -59.96% | Operating Margin (TTM) -1.38% |
Management Effectiveness
Return on Assets (TTM) -11.19% | Return on Equity (TTM) -19.89% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 929373959 | Price to Sales(TTM) 9.7 |
Enterprise Value 929373959 | Price to Sales(TTM) 9.7 | ||
Enterprise Value to Revenue 7.56 | Enterprise Value to EBITDA 0.34 | Shares Outstanding 75166200 | Shares Floating 38394141 |
Shares Outstanding 75166200 | Shares Floating 38394141 | ||
Percent Insiders 0.8 | Percent Institutions 101.5 |
Upturn AI SWOT
Zymeworks Inc. Common Stock
Company Overview
History and Background
Zymeworks Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation bispecific and multispecific antibody therapeutics to improve the treatment of cancer. Founded in 2003, Zymeworks has developed therapeutic platforms and a pipeline of therapeutic candidates.
Core Business Areas
- Research and Development: Focuses on the discovery and development of novel biotherapeutic candidates using its proprietary antibody engineering platforms.
- Oncology: Dedicated to creating innovative cancer therapies leveraging bispecific and multispecific antibody formats.
- Therapeutic Platforms: Development of next generation protein therapeutic platforms
Leadership and Structure
The leadership team comprises experienced professionals in biopharmaceutical research, development, and commercialization. The organizational structure is designed to support efficient drug discovery and clinical development.
Top Products and Market Share
Key Offerings
- Zanidatamab: A HER2-targeted bispecific antibody being developed for HER2-expressing cancers. Market share is still evolving as it is in clinical trials. Competitors include Roche (Herceptin, Perjeta) and other HER2-targeted therapies.
- ZW49: An antibody-drug conjugate (ADC) targeting HER2, being developed for HER2-expressing cancers. Market share is still in development, it is in clinical trials. Competitors include Kadcyla (Roche) and Enhertu (Daiichi Sankyo/AstraZeneca).
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly oncology, is characterized by high growth, intense competition, and significant investment in research and development. Bispecific and multispecific antibodies represent an innovative segment with high potential.
Positioning
Zymeworks is positioned as an innovator in bispecific and multispecific antibody therapeutics, leveraging its proprietary platforms to develop novel cancer therapies.
Total Addressable Market (TAM)
The total addressable market (TAM) for cancer therapies is estimated to be hundreds of billions of dollars. Zymeworks targets specific subsets within this large market with its novel antibody therapies, aiming to capture a significant portion of the HER2-expressing cancer market.
Upturn SWOT Analysis
Strengths
- Proprietary antibody engineering platforms (Azymetric, EFECT)
- Pipeline of bispecific and multispecific antibody candidates
- Experienced leadership team
- Strategic partnerships with pharmaceutical companies
Weaknesses
- Reliance on clinical trial success
- Limited revenue stream (primarily from partnerships)
- High cash burn rate
- Dependence on collaborations
Opportunities
- Successful clinical trials leading to drug approvals
- Expansion of pipeline through internal development and acquisitions
- Strategic partnerships with larger pharmaceutical companies
- Market expansion into new geographies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- ROSH.SW
- AZN
- MRK
- BMY
Competitive Landscape
Zymeworks competes with large pharmaceutical companies and smaller biotechs in the oncology space. Its competitive advantage lies in its proprietary antibody engineering platforms, which enable the development of novel bispecific and multispecific antibodies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by successful platform development, strategic partnerships, and advancement of clinical programs.
Future Projections: Future growth depends on the successful commercialization of its clinical candidates, particularly zanidatamab and ZW49. Analyst estimates vary based on clinical trial outcomes and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing zanidatamab and ZW49 through clinical trials, expanding partnerships with pharmaceutical companies, and investing in platform development.
Summary
Zymeworks is a clinical-stage biopharmaceutical company focused on bispecific and multispecific antibody therapeutics for cancer. The company's strength lies in its innovative technology platforms and promising clinical pipeline, particularly Zanidatamab. However, it faces risks associated with clinical trial outcomes, intense competition, and reliance on future partnerships. Successful commercialization of its lead assets is critical for future growth and shareholder value.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance can change rapidly. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zymeworks Inc. Common Stock
Exchange NASDAQ | Headquaters Middletown, DE, United States | ||
IPO Launch date 2017-04-28 | Chairman of the Board, CEO & President Mr. Kenneth H. Galbraith C.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 273 | Website https://www.zymeworks.com |
Full time employees 273 | Website https://www.zymeworks.com | ||
Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies that enable the selective modulation of recruited cytotoxic immune cells for various therapeutic applications; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidate consists of zanidatamab, a novel bispecific antibody that targets human epidermal growth factor receptor 2 HER2 that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. In addition, the company develops a pipeline of preclinical product candidates. It has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.